Decision Diagnostics : Saga Continues As Investors Bring Suit

In December, the SEC filed a  complaint against Decision Diagnostics and its CEO, Keith Berman, for falsely claiming the company had developed a finger prick blood test that could instantaneously detect COVID-19.  As stated in its complaint, the SEC temporarily suspended trading of Decision Diagnostics' securities on April 23, 2020.

Now, investors have brought suit as well.  Three institutional investors  claim the company - which was already in financial distress as a result of  alleged misappropriations by Berman - falsely disclosed it was developing an at-home COVID-19 test nearing regulatory authorization and then denied investors their right to convert their shares, which were worth millions at the time.  The complaint alleges Berman also falsely announced a distribution partnership with a company owned by members of the plaintiff companies.  Once the alleged fraud became known to the market, the company's stock took a nosedive.  Through their lawsuit, the investor companies seek, among other things, to restrain defendants' assets pending the appointment of a receiver, a complete accounting, and restitution to the investors.

Check back here for updates on this case, as well as others on securities claims relating to companies' COVID-19 disclosures.

Decision Diagnostics Saga Continues as Investors Bring Suit

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Ms Erica T. Jones
Proskauer Rose LLP
Eleven Times Square
(Eighth Avenue & 41st Street)
New York
10036-8299
UNITED STATES
Tel: [phone]
Fax: [phone]
E-mail: [e-mail]
URL: www.proskauer.com

© Mondaq Ltd, 2021 - Tel. [phone] - http://www.mondaq.com, source Business Briefing